Phase 2 Completed N=20 Treatment

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

Ovarian Cancer · primary peritoneal carcinoma

Source: ClinicalTrials.gov NCT00511992 ↗

Enrolled (actual)

Serious AEs

5.0%

Results posted

Jul 2017

Primary outcomePrimary: Number of Patients Able to Complete 6 Cycles of Treatment. — 17 Participants

Summary

The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients Able to Complete 6 Cycles of Treatment.	17	—
SECONDARY Number of Patients Who Experienced Toxicities Associated With Intraperitoneal Cisplatin With Intravenous Paclitaxel and Avastin.	2	—

Eligibility Criteria

Inclusion Criteria

Patients with stage II and III epithelial ovarian carcinoma, primary peritoneal carcinoma, or ovarian carcinosarcoma.
Adequate bone marrow, renal, and hepatic function
Patients must be entered no more than twelve weeks postoperatively

Exclusion Criteria

Patients with epithelial ovarian carcinoma of low malignant potential (borderline carcinomas).
Stage IV or suboptimally debulked disease following primary cytoreductive surgery
Patients who have received prior radiotherapy or chemotherapy.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00511992). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.